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Introduction 53
Ototoxic drugs destroy the sensory hair cells of the auditory and vestibular systems. As a 54 result, treated individuals may acquire irreversible hearing loss, ataxia, nausea and vertigo. 55
Presently, the only way to reduce ototoxic effects is to avoid using these medicines. However, 56 in most cases, ototoxic drugs are part of a life saving therapy. One example, is the family of 57 broad spectrum aminoglycoside antibiotics, which are the most commonly used antibiotic 58 worldwide 1,2 . Prolonged or high dose aminoglycoside treatment damages the hair cells of the 59 cochlea and vestibular apparatus 3 . Individuals with Cystic fibrosis are particularly vulnerable 60 to ototoxic effects, as chronic lung infections (primarily caused by Pseudomonas aeruginosa) 61 require long term aminoglycoside treatment 3 . For individuals acquiring permanent hearing 62 loss, ototoxic effects diminish quality of life. In adults with hearing loss, isolation and 63 depression are common, whilst children can suffer from impaired language and social 64 development [4] [5] [6] [7] . For clinicians, such quality of life implications may impact medical decision-65 making 8 . 66 67 A strategy to mitigate drug induced hearing loss would be revolutionary, but efforts towards 68 this goal have been hampered by limitations of the mouse for studies of ototoxicity. Rodent 69 models are utilised for in vivo mammalian research and the technologies for the manipulation 70 and analysis of the mouse genome have advanced significantly. Hundreds of mouse strains 71 exist that are valuable for investigating hair cell death. However, these resources cannot be 72 effectively utilised without a method to reproducibly induce hearing loss that mimics the 73 human experience. In humans, aminoglycosides are administered intravenously, and the 74 capillaries of the stria vascularis then facilitate passage of the drug from the blood into the 75 cochlea. However, in rodent models, drugs tend to be delivered via sub cutaneous (s.c.) 76 injection, intra peritoneal (i.p.) injection, or directly into the cochlea via more invasive 77 processes. 78
Of the currently utilised techniques to model ototoxicity, trans-tympanic injections are 79 considered to be the most minimally invasive form of drug delivery to the cochlea. However, 80 there is an increased risk of infection and perforations of the tympanic membrane may not 81 heal. Repeated drug delivery can exacerbate these problems and the procedure alone can 82 induce permanent hearing threshold shifts 9,10 . Alternatively, the round window niche (RWN) 83 technique is often used. For this procedure, the middle ear is accessed surgically and the bony 84 tympanic bulla is partially unroofed. A liquid or soaked gelfoam pad is then applied topically 85 to the round window membrane 11 . This technique avoids cochlear perforation, however 86 temporal bone drilling and perilymphatic fistulas can cause acoustic or mechanical damage 11 . 87
Like trans-tympanic injections, the RWN technique is limited to a single treatment. 88
89
Both trans-tympanic injections and RWN techniques rely on passive drug diffusion, which 90 causes a base to apex drug gradient within the cochlea [11] [12] [13] [14] [15] [16] . Other anatomic factors can 91 further impair diffusion, such as Eustachian drainage, round window pseudomembranes, 92 interstitial fluid and wax plugs 10, 17 . A third alternative, cochleostomy with perilymphatic 93 perfusion, ensures consistent drug delivery to target tissues. However, this technique can 94 directly damage the ear and cause permanent hearing loss 11, 18 . The advantage of methods 95 involving direct drug delivery to the cochlea is that systemic toxicities including 96 nephrotoxicity, encephalopathy and peripheral neuropathy can be avoided. However, 97 surgeries are more suited to large rodents such as the gerbil 12, 19 , rat 20,21 , chinchilla 22 or 98 guinea pig 15 . Extensive surgical training and anesthesia is required 16, 23 . In addition, the use of 99 surgical implements such as micropump infusers, tubing or antibiotic soaked gel pads 100 increase the risk of infection or inflammation 11, 19, 23 . 101
Surgical techniques were developed because the adult mouse cochlea appears to be resistant 102 to the effects of systemically delivered aminoglycosides 24,25 . However, within the literature, 103
there are conflicting reports regarding the effects of systemically delivered ototoxic drugs in 104 mice (Table 1) . A number of studies indicate that mice are not susceptible to aminoglycoside 105 induced hearing loss, whilst others suggest that high aminoglycoside doses must be used due 106 to the mouse's high metabolic rate 26, 27 . The most commonly reported successful ototoxic 107 protocol in mice uses 800 mg/kg of kanamycin, given twice daily, s.c., for 15 days [27] [28] [29] [30] . 108
However, the ototoxic outcomes achieved using this protocol vary between studies and some 109 researchers have not been able to replicate ototoxic outcomes using this method 25, 31 . 110 Importantly, kanamycin is not particularly relevant in the modern clinic and the high doses 111
described have toxic effects in mice, causing skin lesions and increased mortality that is 112 difficult to justify ethically 27, 29, 30 . In contrast, immediate intravenous (i.v.) aminoglycoside 113 toxicity is rarely observed in humans 32 . Children and adults routinely receive daily 114 aminoglycoside infusions in the clinic − a practice which has not been accurately modelled in 115 the mouse 32-35 . In the mouse, researchers favour i.p. or s.c. routes of drug delivery. This is 116 because i.v. injections in mice are more difficult than in humans. The mouse lateral tail vein is 117 very small, with a diameter of approximately 300 μm 36 . To facilitate injection, a mouse must 118 first be warmed to encourage vasodilation and restrained to minimise movement. The 119 process is time consuming and requires technical dexterity. Thus, repeated i.v. injections in 120 mice are not routinely performed. However, the i.p. and s.c. modes of delivery are not ideal for 121 aminoglycoside administration. Aminoglycosides are polar molecules, which hinders 122 membrane penetration and drug uptake 32,37 . In contrast, i.v. injection achieves immediate 123 drug uptake and increases the drug's half life 38 . In humans, plasma levels of the 124 aminoglycoside tobramycin achieved by i.v. infusion are double those achieved using i.p. 125 injection 38 . Therefore, we considered that the reported aminoglycoside resistance in mice 126 may be driven by the preponderant use of i.p. and s.c. drug administration (Table 1) . 127
128
The aim of this study was to develop a murine model of aminoglycoside ototoxicity that 129 mirrored clinical practice and outcomes. We hypothesised that repeated, daily i.v. injection of 130 ototoxic aminoglycosides would induce high frequency hearing loss in mice that mimicked 131 human ototoxic pathologies. However, information regarding mouse specific aminoglycoside 132 dosing is limited. Very few studies have used repeated daily i.v. injections and those that have, 133 reported poor outcomes 39 . Human to mouse conversion guidelines, based on body surface 134 area suggest that very high doses of aminoglycosides would be required to achieve the animal 135 equivalent of a human dose, but published LD50 values indicated such doses i.v. would prove 136 lethal 26, 40, 41 . Notably, significant aminoglycoside induced mortality rates are frequently 137 reported in mice, even when alternate routes of delivery are used (Table 1) . 138
139
At present, people with cystic fibrosis have a heightened risk of developing aminoglycoside 140 induced hearing loss, due to the frequent high dose aminoglycoside treatments that they may 141 require 42, 43 . For this patient cohort, tobramycin and amikacin are the most frequently used 142 antibiotics 44-46 . This was reflected in a survey of cystic fibrosis centers in America, in which 143 98.4 % reported tobramycin use and 34.4% reported amikacin use 47 . However, beyond this 144 patient cohort, amikacin is one of the most commonly used antimicrobial agents 48-50 . 145 Therefore, amikacin and tobramycin were selected for use in this study. We first assessed the 146 feasibility of performing repeated daily i.v. injections in mice and then tested whether daily 147 i.v. treatment with amikacin or tobramycin could induce hearing loss in C57BL/6 mice. 148 149 Motor performance was assessed using the Rota-Rod for Mice (47600, Ugo-Basile, Italy) as 228 previously described 67 . Home cages were placed in the testing room, one hour before trials 229 commenced. Then, up to five mice were placed on the Rota rod, facing away from the handler. 230
The rod accelerated from 4-40 rpm during each five-minute trial. The trial ended when the 231 mouse fell from the rotating rod, rotated with the rod more than two consecutive times, or 232 when 300 seconds was reached. Each mouse underwent three trials, with a period of 30 233 minutes between trials. Mice were returned to home-cages when resting. Testing was 234 performed twice on consecutive days, with the first day performed as habituation/training. 235
Trials on the second day were recorded. Latency to fall was recorded by the Rota-Rod CUB 236 software. 237
Tissue Collection and Analysis 238
At 20 weeks of age (immediately post ABR test), anaesthetised mice were euthanised 239 by i.p injection of 400 mg/kg ketamine and 80 mg/kg xylazine in saline. After cessation of 240 breathing, the thoracic cavity was carefully opened. A cannula was inserted into the left 241 ventricle and a small perforation was made in the right atrium. PBS was perfused through 242 each animal for five minutes, followed by a five-minute flush of 4% paraformaldehyde. 243
Kidneys and cochleae were immediately dissected and stored in 4% paraformaldehyde. After each injection, mice treated with 40 or 80 mg/kg were moderately inactive for a short 279 period of time (less than 5 minutes). Mice given 120 mg/kg commonly exhibited rapid 280 breathing and prostration (approximately 30 seconds), followed by a brief period of 281 hypoactivity. These effects occurred for each daily injection, with mice recovering quickly 282 each time. However, two mice were removed from the 120 mg/kg cohort (2 of 10) due to 283 localised swelling of the tail. Treatment with 145 mg/kg of amikacin was immediately lethal 284 in two mice (2 of 2). As a result, treatment with 145 mg/kg was not continued in the 285 remaining cohort. 286 287 Tobramycin 288
Mild prostration and rapid breathing was observed in the 40 mg/kg tobramycin cohort 289 (approximately 30 seconds) followed by hypoactivity. Higher tobramycin doses were not 290 tested, as the prostration observed at 40 mg/kg was similar to that seen in the highest 291 tolerable amikacin treatment group. 292 293 Aminoglycosides induced mild low frequency hearing loss 294
Hearing thresholds were assessed using the Auditory Brainstem Response (ABR) at two and 295 twenty weeks post treatment. Two weeks post-treatment, average hearing thresholds were 296 unchanged in the low dose amikacin group at all frequencies tested. In contrast, the 80 and 297 120 mg/kg amikacin groups, and the 40 mg/kg tobramycin group showed altered hearing 298 thresholds when compared with controls (Fig 1) . The small, threshold shift was only present 299 at low frequencies (4-8 kHz). At twenty weeks no significant differences in auditory function 300 were observed between control and treatment groups. Cochlear histology was also 301 unremarkable ( Fig 2) . 302 303 Aminoglycoside treatment did not impair Rota-Rod performance. 304
In humans, ototoxic aminoglycosides frequently cause vestibular impairment. In some cases, 305 aminoglycoside toxicity may be greater in the vestibular apparatus than the cochlea 70 . 306
However, there are contrasting reports regarding the vestibular toxicity of amikacin and 307 tobramycin 71,72 . Generally, amikacin and tobramycin are considered to be more cochleotoxic 308 than vestibulotoxic, however there is certainly evidence within the literature showing that 309 both are able to induce permanent vestibular damage 73-78 . In humans, 310
Electronystagmography is the gold standard of vestibular analysis 79 . However, measuring the 311 vestibulo-ocular reflex in mice is more difficult and rarely attempted. Instead, the accelerating 312 rotor rod is commonly used as a measure of gross motor coordination and balance in rodent 313 models. Poor performance in this test has been validated as a measure of dysfunction of the 314 hair cells or stereocillia [80] [81] [82] . In this mouse study, the accelerating rotor rod was used to 315 assess whether vestibular function was impaired by aminoglycoside treatment. On average, 316 the mice in all treatment and control groups performed well, balancing on the accelerating 317 apparatus for between three and four minutes (Fig 3) . There was no significant difference 318 between groups (one way ANOVA p = 0.61) 319 320 Nephrotoxicity was not observed in aminoglycoside treated mouse kidneys. 321
In humans, aminoglycoside antibiotics can cause subclinical kidney damage, leading to 322 chronic kidney disease (CKD) which manifests at the level of the glomerulus and tubules 76 . To 323 identify acute injury, creatine levels are often measured. However, this measure has 324 previously underrepresented chronic kidney damage 76,83 . Alternatively, histological analysis 325 provides a clear indication of drug induced kidney damage 83 . Similarly, in mice, histological 326 signs of CKD can be present with no changes in creatinine and BUN (reviewed in Rabe et al. 327 84 ). Therefore, kidney histology was used to ascertain whether the daily i.v. aminoglycoside 328 treatments performed in this study resulted in damage to the mouse kidney ( Fig 4A-C) . 329
Histological changes expected in a kidney damaged by aminoglycosides include extensive 330 tubular damage, scarring or interstitial fibrosis. Dilated atrophic tubules may also be present 331 due to incomplete focal regeneration 85 . Within this study, no such morphological changes 332 were present in the nephrons of aminoglycoside treated mice (Table 2 ). Protein casts were 333 observed in two mice, one from the 80 mg/kg amikacin group, and one from the 120 mg/kg 334 amikacin group. These casts were few in number and considered by the expert veterinary 335 pathologist to be incidental findings. Similarly, very mild pyelitis was observed in one saline 336 control, which is a common incidental finding of no clinical significance. 337 338 occurs at the same frequency (4-8 kHz). From this, it is tempting to suggest that hair cells 363 correlating with frequency specific perception are more susceptible to ototoxicity. However, 364 ototoxic hearing loss in humans has a distinct pattern, with hair cells in the base of the cochlea 365 dying at a greater rate than those situated towards the apex. Due to cochlear tonotopy, this 366 cell death pattern causes high-frequency hearing loss, which is above 2000Hz in humans. In 367 vitro studies utilising mouse cochlear explants have shown a similar basal to apical pattern of 368 cell death in response to aminoglycoside treatment. Therefore, a similar pattern of cell death 369 in vivo would be expected to induce hearing loss above 16kHz in mice, because the auditory 370 perception range of mice is higher than that of humans. Furthermore, the small differences 371 observed between the hearing thresholds of treated and un-treated mice at 10 weeks were no 372 longer present at 20 weeks of age. And, imaging indicated that hair cells were present in the 373 apical turn of cochleae collected from aminoglycoside treated mice. Therefore, the ABR results 374 obtained at 10 weeks, although statistically significant, must be viewed with caution. 375 376 Generally, low frequency hearing loss may be indicative of a conductive issue, or the result of 377 inner ear hydrops. However, in both cases a much larger threshold shift than 5dB SPL is 378 expected 65,86-88 . Furthermore, a condition such as hydrops would be expected to cause severe 379 progressive hearing loss and vestibular impairment, which we did not observe in 380 aminoglycoside treated mice 89, 90 . It is possible that the small differences initially observed, 381
were compounded by the limitations of ABR Testing. In this study, ABR thresholds were 382 measured to the nearest 5 dB SPL. Therefore, a mouse with a hearing threshold between 31 383 and 35 dB SPL would record a threshold of 35 dB SPL. This can result in the magnification of 384 insignificant threshold shifts. However, the trend towards low frequency hearing changes was 385 consistent in the 10 week old aminoglycoside treated mice and there is some previous 386 evidence that low frequency hearing loss has been caused by aminoglycoside treatments in 387 mice 91,92 . Nevertheless, the small and short-lived differences observed in this study would 388 likely prove inadequate when testing oto-protective substances experimentally. Very large 389 animal cohorts would be required to detect appreciable differences between treatment 390 groups and given the labour intensive nature of i.v. injections, such cohorts would be difficult 391 to generate and manage. 392
393
There are however, more sensitive methods than ABR testing available for assessing cochlear 394 damage in the mouse. For example, otoacoustic emissions that have been produced by the 395 outer hair cells as they act to amplify a sound wave within the cochlea can be recorded in the 396 ear canal by Distortion Product Otoacoustic Emission (DPOAE) testing. These emissions 397 provide a more sensitive measure of outer hair cell function 93, 94 . Additionally, scanning 398 electron microscopy or histology combined with immunohistochemistry has previously been 399 used to investigate subtle cell death patterns 31,61,95 . However, the goal of this study was to 400 achieve robust ABR threshold shifts similar to those observed in humans to ensure a clinically 401 relevant model of ototoxicity. In humans, the reported prevalence of aminoglycoside 402 ototoxicity can be quite variable, affecting between 21 % to 83 % of individuals 42,96-101 . 403
However, when hearing threshold shifts are observed, they are usually greater than 20 dB SPL 404 and often in more than one frequency 96,97,99,101 . For amikacin specifically, Javadi et al. ototoxic outcomes in only 24% of treated individuals that had received 22.5 mg/kg daily for 408 19 days. However, the hearing loss measured in these individuals was greater, with an 409 average threshold shift of 37-39 dB SPL at the higher frequencies (4-8 kHz) 103 . For 410 tobramycin, Pederson et al. reported that 15 mg/kg daily for 14 days induced a threshold shift 411 of 15-30 dB SPL, also in two high frequencies, for 32% of those treated. Such large ABR 412 threshold shifts were not induced by the aminoglycoside dosing regimens tested in this study, 413 which were 5-7 times higher than the maximum recommended human dose 414 415 Notably, allometric scaling suggests that even higher doses of aminoglycosides would be 416 required to match mouse and human dosing. For example, human to mouse conversion 417 guidelines based on body surface area, suggest that a human dose must be multiplied by 12.3 418 to achieve an equivalent dose in the mouse (outlined in Nair and Jacob, 2016) 26,40,41 . 419
However, such conversions remain controversial and in our hands, high doses were 420 immediately lethal. Some previous studies have shown that mice tolerate higher 421 aminoglycoside doses when given via s.c. and i.p. injection (Table 1) . However, this may 422 reflect the slower drug uptake achieved using i.p./s.c. injections 104 , and an overall reduced 423 drug uptake due to the poor membrane penetration of aminoglycosides 32,37 . Indeed, 424 tobramycin plasma levels achieved by i.v. infusion are double those achieved using i.p. 425 injection in humans 38 . Notably, high mortality is still a frequent outcome when mice are given 426 aminoglycosides i.p. or s.c. (Table 1) . 427
Such immediate life threatening responses to aminoglycosides rarely occur in humans. This 428 may indicate that humans have an intrinsic ability to tolerate systemic aminoglycosides when 429 compared to mice, and as a result only susceptible tissues such as the kidney and ear are 430 damaged. Alternatively, infusion rate is an important factor to consider. In this study, mice 431 received daily i.v. injections, which were relatively rapid (approx. 30-40 s). In contrast, daily 432 aminoglycosides treatments can be given via i.v. infusion over 30 minutes in humans. This is 433 an aspect of human treatment that is particularly difficult to recapitulate in mice. Implantable 434 infusion pumps can provide constant and slow i.v. drug delivery in mice. However, these 435 pumps have a small reservoir volume (100-200 µl), which limits their capacity for 436 aminoglycoside delivery. 437
438
Overall, the utility of mice to model aminoglycoside ototoxicity remains controversial. Some 439 studies have reported success using kanamycin, whereas a number have found mice to be 440 resistant to ototoxic drugs 25,27,29,62 . Our finding, that daily i.v. injections of tobramycin or 441 amikacin did not induce significant high frequency hearing loss in C57BL/6 mice offers 442 further support to the hypothesis that mice are resistant to aminoglycoside ototoxicity. 443
444
There may be a number of reasons why systemic aminoglycosides are unable to cause hearing 445 loss in mice. It has been proposed that the mouse's high metabolic rate and rapid drug 446 clearance prevents serum levels reaching ototoxic levels 25, 27 . However, Wu et al. previously 447 suggested that kanamycin induced hair cell damage is greatest in BALB/c mice, even though 448 these mice clear kanamycin from their system faster than C57BL/6 and CBA mice 27 . 449 Furthermore, i.v. injections provide immediate systemic drug distribution and increase the 450 half life of aminoglycosides 38 . This should ensure rapid drug delivery to the ear. Therefore, an 451 alternate hypothesis regarding ototoxic resistance is that the blood-endolymph barrier in 452 mice is less permeable to aminoglycosides than in other mammals. strains of mice, the pigmented C57BL/6 strain is the most commonly used mouse in 475 biomedical research and many genetically altered strains have been developed from mice 476 with pigmented colouring 113 . However, with advances in gene editing technology such as 477 CRISPR/cas9 it is becoming easier to modify strains with a desirable genetic background. 478
479
For this study, we used amikacin and tobramycin, which are the most frequently used ototoxic 480 aminoglycosides in clinical practice. However, some studies have suggested that kanamycin is 481 the most ototoxic aminoglycoside in mice 27, 29 . It is possible that intravenous kanamycin may 482 have had a stronger affect than amikacin or tobramycin. However, as discussed above, the 483 reported ototoxicity of kanamycin in mice is controversial. Alternatively, co-administration of 484 loop diuretics such as furosemide, have been used to disrupt the blood-endolymph barrier 485 and enhance ototoxic outcomes in mice 91, 95, [114] [115] [116] . Loop diuretics cause vasoconstriction 486 within the stria vascularis and strial ischemia follows. This causes dysregulation of the blood-487 endolymph barrier, allowing aminoglycosides to accumulate within the cochlear endolymph 488 [117] [118] [119] . It is likely that furosemide co-administration would enhance the ototoxicity of i.v. 489 administered amikacin or tobramycin. Indeed, the ototoxic effects of furosemide-490 aminoglycoside co-treatments appear to be consistent and easily reproduced, and a recent 491 study has reported hearing impairment in juvenile mice treated with an amikacin-furosemide 492 combination (P14-21, n = 4) 120 . However, the use of furosemide can be confounding for a 493 number of reasons, particularly when assessing otoprotective substances. Furosemide is an 494 ototoxic compound, causing rapid, transient hearing loss 117,118,121 . However, permanent 495 furosemide ototoxicity can occur 122-124 . Importantly, combined furosemide-kanamycin 496 treatments in mice do not achieve ototoxicity that mimics human aminoglycoside induced 497 hair cell death. Instead, extensive cochlear damage and a marked inflammatory response 498 results in hearing loss across all frequencies 91 . Furthermore, furosemide significantly 499 increases aminoglycoside serum levels, which often leads to unacceptable mortality (up to 500 75% mortality depending on dose) 91, 116, 118, [125] [126] [127] . Such mortality is difficult to justify when 501 the extensive cochlear destruction achieved implies an alternate mechanism of injury. As a 502 result, the benefits afforded by otoprotective compounds in a furosemide ototoxicity model 503 may be related to a number of factors beyond hair cell protection. 504
505
Mice are also considered to be resistant to aminoglycoside nephrotoxicity 128-130 , with 506 pigmented strains significantly more resistant to nephropathy than non-pigmented strains 507 [131] [132] [133] [134] [135] . Previous studies using the highly nephrotoxic aminoglycoside gentamycin have 508 induced kidney damage in white mice [136] [137] [138] And, the use of furosemide in conjunction with 509 aminoglycosides has also induced nephropathy in mice 126,139 . However, we observed no 510 evidence of kidney damage in amikacin or tobramycin treated C57BL/6 mice, despite 511 frequently observing signs of immediate systemic toxicity such as significant prostration. The 512 absence of kidney damage may be due to the intrinsic resistance of C57BL/6 mice to 513 nephropathy, or may be due to the significantly lower nephrotoxic properties of tobramycin 514 and amikacin 140,141 . It is possible that a longer treatment period could enhance the oto-and 515 nephro-toxicities of aminoglycosides in this i.v. model. However, tail veins can become 516 difficult to visualise after a number of injections. Presently, the surgical approach of directly 517 applying compounds to the mouse's ear remains a consistent way to deafen mice with 518 ototoxic aminoglycosides. This technique bypasses the stria vascularis, allowing for drug entry 519 via the round window, reducing systemic toxicities and mortality. However, confounding 520 issues such as physical damage, the inflammatory response, variable drug diffusion and the 521 level of skill required are problematic in an experimental setting, limiting the utility of this 522 model. 523
524
Studies utilising fluorescently labelled aminoglycosides have also highlighted the importance 525 of the strial capillary network and marginal cells as an entry point for aminoglycosides [142] [143] [144] [145] . 526 However, the process by which aminoglycosides are trafficked from capillary, to marginal 527 cells and finally the endolymph is not yet understood. Future research regarding the blood-528 endolymph barrier in mice may elucidate the mechanism underlying ototoxicity resistance 529 and provide further opportunity for developing otoprotective strategies. 530 531 Summary 532
The aim of this study was to develop a murine model of aminoglycoside ototoxicity that 533 mimicked clinical practice. Previous studies have suggested that mice are not susceptible to 534 aminoglycoside induced hearing loss. However, the standard care methodology utilised for 535 human aminoglycoside infusions have not been accurately modelled in the mouse. In humans, 536 aminoglycosides are predominantly given i.v., whereas i.p. or s.c. routes of drug delivery have 537 been used in the mouse. We hypothesised that repeated, daily i.v. injection of ototoxic 538 aminoglycosides would induce high frequency hearing loss similar to that observed in 539 aminoglycoside treated humans. We demonstrated that daily i.v. injections are achievable but 540 C57BL/6 mice do not appear to be a suitable model for systemic aminoglycoside ototoxic 541 investigations (in vivo). Daily i.v. aminoglycoside injections of 80-120 mg/kg of amikacin and 542 40 mg/kg tobramycin induced significant signs of systemic toxicity, such as rapid breathing 543 and prostration in treated mice. Higher doses given i.v. were immediately lethal. This regimen 544 was unable to achieve strong ABR threshold shifts in mice mimicking the high frequency 545
hearing loss that occurs in aminoglycoside treated humans. For example, tobramycin has been 546 shown to induce a hearing loss of ~39 dB SPL at two high frequencies in humans after 14 days 547 of treatment 99 and for some individuals, ototoxic outcomes can worsen over time 146 . In this 548 study, no significant high frequency hearing loss was observed in aminoglycoside treated 549 C57BL/6 mice at either 2 or 12 weeks post treatment. However, age related hearing loss 550 typical of the C57BL/6 strain was observed in both the control and aminoglycoside treated 551 mice at 20 weeks of age. We conclude that daily i.v. injections of amikacin or tobramycin do 552 not achieve a robust model of ototoxicity in C57BL/6 mice. 553 
